Quick Answer
Omega-3 Inflammation Randomized Trial has evidence relevant to strength of evidence and what the studies can or cannot prove, but conclusions should stay close to the cited sources. One representative finding is: Effects of omega-3 PUFA-enriched egg consumption on metabolic parameters in elderly adults with metabolic syndrome: study protocol for a randomized controlled trial
Key Takeaways
- 01Effects of omega-3 PUFA-enriched egg consumption on metabolic parameters in elderly adults with metabolic syndrome: study protocol for a randomized controlled trial [Yang H (2026)]
- 02The results showed that CRP levels increased from 9.86 ± 12.64 to 11.46 ± 22.23 mg/L in the intervention group and from 5.24 ± 9.01 to 5.61 ± 7.93 mg/L in the control group (p = 0.11). [Shafaei Kachaei H (2026)]
- 03Similarly, IL-6 levels increased from 17.84 ± 14.08 to 81.82 ± 66.22 pg/mL in the intervention group and from 14.96 ± 18.41 to 56.73 ± 115.45 pg/mL in the control group (p = 0.53). [Shafaei Kachaei H (2026)]
- 04○ Omega-3 fatty acids have anti-inflammatory properties and are reported to be potentially beneficial in reducing inflammation associated with CKD, but the evidence regarding the effectiveness of omega-3 supplements in reducing inflammatory markers in this population remains inconsistent. [Shafaei Kachaei H (2026)]
The current Migaku evidence database contains 2 reusable source documents for Omega-3 Inflammation Randomized Trial. This answer focuses on strength of evidence and what the studies can or cannot prove.
- Effects of omega-3 PUFA-enriched egg consumption on metabolic parameters in elderly adults with metabolic syndrome: study protocol for a randomized controlled trial [Yang H (2026); evidence level 2]
- The results showed that CRP levels increased from 9.86 ± 12.64 to 11.46 ± 22.23 mg/L in the intervention group and from 5.24 ± 9.01 to 5.61 ± 7.93 mg/L in the control group (p = 0.11). [Shafaei Kachaei H (2026); evidence level 2]
- Similarly, IL-6 levels increased from 17.84 ± 14.08 to 81.82 ± 66.22 pg/mL in the intervention group and from 14.96 ± 18.41 to 56.73 ± 115.45 pg/mL in the control group (p = 0.53). [Shafaei Kachaei H (2026); evidence level 2]
- ○ Omega-3 fatty acids have anti-inflammatory properties and are reported to be potentially beneficial in reducing inflammation associated with CKD, but the evidence regarding the effectiveness of omega-3 supplements in reducing inflammatory markers in this population remains inconsistent. [Shafaei Kachaei H (2026); evidence level 2]
- This randomized controlled trial aimed to evaluate the effects of omega-3 fatty acids supplementation on inflammatory markers in patients with CKD undergoing hemodialysis. [Shafaei Kachaei H (2026); evidence level 2]
Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording.
This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.
Sources